newsfilter
← Latest News
GlobeNewswire·

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for